Akbari Vajihe, Mir Mohammad Sadeghi Hamid, Jafrian-Dehkordi Abbas, Abedi Daryoush, Chou C Perry
Department of Pharmaceutical Biotechnology, Isfahan Pharmaceutical Research Center, Faculty of Pharmacy, Isfahan University of Medical Sciences, Hezar Jarib Avenue, Isfahan, Iran.
J Ind Microbiol Biotechnol. 2014 Jun;41(6):947-56. doi: 10.1007/s10295-014-1437-0. Epub 2014 Mar 27.
The human epidermal growth factor receptor (HER) family plays an important role in cell growth and signaling and alteration of its function has been demonstrated in many different kinds of cancer. Receptor dimerization is necessary for the HER signal transduction pathway and tyrosine kinase activity. Recently, several monoclonal antibodies have been developed to directly interfere with ligand-HER receptor binding and receptor dimerization. A single chain variable fragment (ScFv) is a valuable alternative to an intact antibody. This report describes the production and purification of an ScFv specific for domain II of the HER2 receptor in Escherichia coli BL21 (DE3) cytoplasm. The majority of expressed of anti-her2his-ScFv protein was produced as inclusion bodies. A Ni-NTA affinity column was used to purify the anti-her2his-ScFv protein. The molecular weight of anti-her2his-ScFv protein was estimated to be approximately 27 kDa, as confirmed by SDS-PAGE and Western blotting assay. The anti-her2his-ScFv showed near 95 % purity and reached a yield of approximately 29 mg/l in flask fermentation. The purified anti-her2his-ScFv showed its biological activity by binding to HER2 receptor on the surface of BT-474 cells. This ScFv may be a potential pharmaceutical candidate for targeting tumour cells overexpressing HER2 receptor.
人表皮生长因子受体(HER)家族在细胞生长和信号传导中发挥着重要作用,其功能改变已在多种癌症中得到证实。受体二聚化对于HER信号转导途径和酪氨酸激酶活性是必需的。最近,已开发出几种单克隆抗体以直接干扰配体-HER受体结合和受体二聚化。单链可变片段(ScFv)是完整抗体的一种有价值的替代物。本报告描述了在大肠杆菌BL21(DE3)细胞质中生产和纯化针对HER2受体结构域II的ScFv。大多数表达的抗her2his-ScFv蛋白以包涵体形式产生。使用镍-氮三乙酸(Ni-NTA)亲和柱纯化抗her2his-ScFv蛋白。经十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质免疫印迹分析证实,抗her2his-ScFv蛋白的分子量估计约为27 kDa。抗her2his-ScFv的纯度接近95%,在摇瓶发酵中的产量约为29 mg/l。纯化的抗her2his-ScFv通过与BT-474细胞表面的HER2受体结合显示出其生物活性。这种ScFv可能是靶向过表达HER2受体的肿瘤细胞的潜在药物候选物。